CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

US-China biotech NeuShen gets $80M to develop brain-health drugs

Positive
AI Analysis

Summary

NeuShen Therapeutics, a US-China biotech firm, secured over $80 million in Series B funding to advance three clinical-stage brain-health drugs.

Importance:5/10
Sentiment:
0.70
Series B fundingbrain-healthUS-China biotechclinical-stage
Related Companies

Read the original article

Published by Endpoints News on September 4, 2026 2:47 PM

Read Original